The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
STAT3 in Cancer—Friend or Foe?
Open accessAbstract
The roles and significance of STAT3 in cancer biology have been extensively studied for more than a decade. Mounting evidence has shown that constitutive activation of STAT3 is a frequent biochemical aberrancy in cancer cells, and this abnormality directly contributes to tumorigenesis and shapes many malignant phenotypes in cancer cells. Nevertheless, results from more recent experimental and clinicopathologic studies have suggested that STAT3 also can exert tumor suppressor effects under specific conditions. Importantly, some of these studies have demonstrated that STAT3 can function either as an oncoprotein or a tumor suppressor in the same cell type, depending on the specific genetic background or presence/absence of specific coexisting biochemical defects. Thus, in the context of cancer biology, STAT3 can be a friend or foe. In the first half of this review, we will highlight the “evil” features of STAT3 by summarizing its oncogenic functions and mechanisms. The differences between the canonical and non-canonical pathway will be highlighted. In the second half, we will summarize the evidence supporting that STAT3 can function as a tumor suppressor. To explain how STAT3 may mediate its tumor suppressor effects, we will discuss several possible mechanisms, one of which is linked to the role of STAT3β, one of the two STAT3 splicing isoforms. Taken together, it is clear that the roles of STAT3 in cancer are multi-faceted and far more complicated than one appreciated previously. The new knowledge has provided us with new approaches and strategies when we evaluate STAT3 as a prognostic biomarker or therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383 · cited 2×
“autocrine or paracrine stimulatory pathways include IL-6, IL-10, IL-11, IL-21, IL-23, leukemia inhibitory factor and oncostatin [58].”
BackgroundSTATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 4×
“Subsequently, the phosphorylated STAT3 (pSTAT3) molecules form homodimers, which migrate to the nuclei where they bind to the promoters of various target genes and regulate their transcriptions [1,2].”
BackgroundInfluentialProtein Tyrosine Phosphatases in the Human Genome
Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J., & Mustelin, T. (2004) · Cell · doi:10.1016/j.cell.2004.05.018 · Cited by 1,886
SOCS proteins, cytokine signalling and immune regulation
Yoshimura, A., Naka, T., & Kubo, M. (2007) · Nature Reviews Immunology · doi:10.1038/nri2093 · Cited by 1,580
Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality
Takeda, K., Noguchi, K., Shi, W., Tanaka, T., Matsumoto, M., Yoshida, N., Kishimoto, T., & Akira, S. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.8.3801 · Cited by 1,323 · cited 1×
“Briefly, its biological importance is highlighted by the observation that STAT3 gene ablation in mice results in embryonic lethality that occurs 6–7 days after inception [9].”
BackgroundConstitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis
Niu, G., Wright, K. L., Huang, M., Song, L., Haura, E., Turkson, J., Zhang, S., Wang, T., Sinibaldi, D., Coppola, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205260 · Cited by 1,207
Function of Mitochondrial Stat3 in Cellular Respiration
Wegrzyn, J., Potla, R., Chwae, Y.-J., Sepuri, N. B. V., Zhang, Q., Koeck, T., Derecka, M., Szczepanek, K., Szelag, M., Gornicka, A., et al. (2009) · Science · doi:10.1126/science.1164551 · Cited by 1,014 · cited 2×
“Mitochondrial STAT3: In 2009, two Science papers simultaneously reported the function of STAT3 present in the mitochondria [137,138].”
BackgroundQuintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843 · cited 1×
“JAK2-V617F and other JAK mutants are known to activate STAT3 and contribute to the pathogenesis of chronic myeloproliferative neoplasms and leukemias [70–73].”
BackgroundIliopoulos, D., Jaeger, S. A., Hirsch, H. A., Bulyk, M. L., & Struhl, K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.07.023 · Cited by 830 · cited 3×
“Through multiple pathways, activated NF-κB increases the production of IL-6, which in turn sustains the activation of STAT3 [76].”
BackgroundInfluentialStat3 Dimerization Regulated by Reversible Acetylation of a Single Lysine Residue
Yuan, Z.-L., Guan, Y.-J., Chatterjee, D., & Chin, Y. E. (2005) · Science · doi:10.1126/science.1105166 · Cited by 790 · cited 1×
“demonstrated that histone acetyltransferase p300 is responsible for STAT3 acetylation at K685, and this process can be reversed by histone deacetylase 1 [128].”
BackgroundLevy, D. E., & Lee, C.-K. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215650 · Cited by 734
Gao, S. P., Mark, K. G., Leslie, K., Pao, W., Motoi, N., Gerald, W. L., Travis, W. D., Bornmann, W., Veach, D., Clarkson, B., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31871 · Cited by 666
Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9940 · Cited by 633 · cited 1×
“In other studies, it has been demonstrated that STAT3β can abolish the transcriptional activation of several STAT3 downstream targets including Cyclin D1, Bcl-xL and Mcl-1, leading to inhibition of tumor growth and promotion of apoptosis [174–176].”
BackgroundYang, J., Liao, X., Agarwal, M. K., Barnes, L., Auron, P. E., & Stark, G. R. (2007) · Genes & Development · doi:10.1101/gad.1553707 · Cited by 611
Takeda, K., Kaisho, T., Yoshida, N., Takeda, J., Kishimoto, T., & Akira, S. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.4652 · Cited by 584 · cited 1×
“In another study, STAT3 was shown to be important in mediating the anti-apoptotic effect of IL-6 in the presence of a low-serum culture environment [13].”
BackgroundGritsko, T., Williams, A., Turkson, J., Kaneko, S., Bowman, T., Huang, M., Nam, S., Eweis, I., Diaz, N., Sullivan, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1752 · Cited by 563
STAT3 Is Required for Proliferation and Maintenance of Multipotency in Glioblastoma Stem Cells
Sherry, M. M., Reeves, A., Wu, J. K., & Cochran, B. H. (2009) · Stem Cells · doi:10.1002/stem.185 · Cited by 478
Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation
Yang, J., Chatterjee-Kishore, M., Staugaitis, S. M., Nguyen, H., Schlessinger, K., Levy, D. E., & Stark, G. R. (2005) · Cancer Research · doi:10.1158/0008-5472.939.65.3 · Cited by 405
STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors
Lee, H., Deng, J., Kujawski, M., Yang, C., Liu, Y., Herrmann, A., Kortylewski, M., Horne, D., Somlo, G., Forman, S., et al. (2010) · Nature Medicine · doi:10.1038/nm.2250 · Cited by 395 · cited 2×
“revealed another positive feedback loop that confers STAT3 with a persistent activation property in cancer cells as well as the immune cells present in the tumor microenvironment [77].”
BackgroundSTAT signaling in head and neck cancer
Song, J. I., & Grandis, J. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203483 · Cited by 374
Caldenhoven, E., van Dijk, T. B., Solari, R., Armstrong, J., Raaijmakers, J. A. M., Lammers, J.-W. J., Koenderman, L., & de Groot, R. P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.22.13221 · Cited by 373
STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-α3
Liu, L., McBride, K. M., & Reich, N. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501643102 · Cited by 348 · cited 1×
“First, un-phosphorylated STAT3 has been found to migrate to the nucleus with the help of importin-α3 [130].”
BackgroundIdentification of a PTEN-regulated STAT3 brain tumor suppressor pathway
de la Iglesia, N., Konopka, G., Puram, S. V., Chan, J. A., Bachoo, R. M., You, M. J., Levy, D. E., DePinho, R. A., & Bonni, A. (2008) · Genes & Development · doi:10.1101/gad.1606508 · Cited by 336
Alonzi, T., Maritano, D., Gorgoni, B., Rizzuto, G., Libert, C., & Poli, V. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1621-1632.2001 · Cited by 329
Auernhammer, C. J., Bousquet, C., & Melmed, S. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.12.6964 · Cited by 284
Activation of STAT3 is a marker of poor prognosis in human colorectal cancer
Kusaba, T., Nakayama, T., Yamazumi, K., Yakata, Y., Yoshizaki, A., Inoue, K., Nagayasu, T., & Sekine, I. (2006) · Oncology Reports · doi:10.3892/or.15.6.1445 · Cited by 238 · cited 1×
“In a study of colorectal cancer, pSTAT3 expression was found to significantly correlate with the depth of tumor invasion, status of lymph node, metastasis and tumor stage [29].”
BackgroundThe STAT3 isoforms α and β have unique and specific functions
Maritano, D., Sugrue, M. L., Tininini, S., Dewilde, S., Strobl, B., Fu, X., Murray-Tait, V., Chiarle, R., & Poli, V. (2004) · Nature Immunology · doi:10.1038/ni1052 · Cited by 234
Antitumorigenic potential of STAT3 alternative splicing modulation
Zammarchi, F., de Stanchina, E., Bournazou, E., Supakorndej, T., Martires, K., Riedel, E., Corben, A. D., Bromberg, J. F., & Cartegni, L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1108482108 · Cited by 176
Barbieri, I., Pensa, S., Pannellini, T., Quaglino, E., Maritano, D., Demaria, M., Voster, A., Turkson, J., Cavallo, F., Watson, C. J., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2840 · Cited by 148 · cited 1×
“transcriptionally up-regulating the expression of focal adhesion-associated proteins [16,121].”
BackgroundBiethahn, S., Alves, F., Wilde, S., Hiddemann, W., & Spiekermann, K. (1999) · Experimental Hematology · doi:10.1016/s0301-472x(99)00017-x · Cited by 74
Huang, Y., Qiu, J., Dong, S., Redell, M. S., Poli, V., Mancini, M. A., & Tweardy, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704548200 · Cited by 65
Ng, I. H. W., Ng, D. C. H., Jans, D. A., & Bogoyevitch, M. A. (2012) · Biochemical Journal · doi:10.1042/bj20120941 · Cited by 63 · cited 3×
“M in murine embryonic fibroblasts [171].”
BackgroundJAK2 V617F uses distinct signalling pathways to induce cell proliferation and neutrophil activation
Oku, S., Takenaka, K., Kuriyama, T., Shide, K., Kumano, T., Kikushige, Y., Urata, S., Yamauchi, T., Iwamoto, C., Shimoda, H. K., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08249.x · Cited by 51
Cited by
JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Owen, K. L., Brockwell, N. K., & Parker, B. S. (2019) · Cancers · doi:10.3390/cancers11122002 · Cited by 714
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
Environmental immune disruptors, inflammation and cancer risk
Thompson, P. A., Khatami, M., Baglole, C. J., Sun, J., Harris, S. A., Moon, E.-Y., Al-Mulla, F., Al-Temaimi, R., Brown, D. G., Colacci, A. M., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv038 · Cited by 227
“STATs, like other transcription factors, have a dual and self-perpetuating role in inflammation and, like other similar molecules, is considered to be both a friend and a foe in tumorigenesis (33).”
BackgroundSTAT3, a master regulator of anti-tumor immune response
Rébé, C., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11091280 · Cited by 129
Phosphoinositide 3-kinase signaling can modulate MHC class I and II expression
Chandrasekaran, S., Sasaki, M., Scharer, C. D., Kissick, H. T., Patterson, D. G., Magliocca, K. R., Seykora, J. T., Sapkota, B., Gutman, D. A., Cooper, L. A., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0545 · Cited by 61
Metadata
- Authors
- Zhang, H.-F., & Lai, R.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2014-07-03
- Volume
- 6
- Issue
- 3
- Pages
- 1408-1440
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W2016191221
- Cited by
- 219
- References
- 35
- FWCI
- 4.60
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.